Announcing the 2025 Collaborative Research Training Award Recipients!!!
We are excited to announce the recipients of the 2025 NMD4C Collaborative Research Training Awards, which supports Canadian trainees in their efforts to advance neuromuscular disease research while strengthening national collaboration among neuromuscular research laboratories.
Congratulations to the following awardees:
- Madison Garibotti, MSc, PhD Candidate(York University)
- Home Supervisor: Dr. Christopher Perry
- Host Supervisor: Dr. Jean-Philippe Leduc-Gaudet
- Marion Boyer, PhD Candidate (CERVO)
- Home Supervisor: Dr. Silvia Pozzi
- Host Supervisor: Dr. Thomas Durcan
- Dr. Emilie Groulx-Boivin, MSc Candidate (Montreal Children's Hospital, McGill University)
- Home Supervisor: Dr. Maryam Oskoui
- Host Supervisor: Dr. Adam Kirton
- Dr. Jeremy Slayter, MSc Candidate (Dalhousie University)
- Home Supervisor: Dr. Colleen O'Connell
- Host Supervisor: Dr. Gordon Jewett
These talented individuals will be using their awards to visit other Canadian laboratories, gaining hands-on experience and fostering collaboration within the neuromuscular research community.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.